secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-08-25T23:59:59+00:00
Accession:  0001517022-23-000032
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia reports Q2 net loss $11.2M, plans vadadustat NDA resubmission by Q3 end
------------------------------------------------------------------------------

- Net product revenue Auryxia $42.2M (-2.5% YoY); reaffirms FY 2023 guidance $175-180M.
- Total revenue $56.4M (down from $126.4M, largely due to Otsuka termination fee in prior year).
- Cash $53.6M; expects to fund operations for at least 12 months.
- Identified accounting errors on product returns; material weakness; will amend 2020-2022 financials.
- Plan to resubmit vadadustat NDA by Sept 30, 2023; potential PDUFA March 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000032/0001517022-23-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000032/akba-20230825.htm
  HTML page:      https://secwatch.observer/filing/0001517022-23-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer